Introduction
Nanomaterials have a broad range of applications in technology and biological medicine because of the unique properties of nanoparticles (NPs), which render nanomaterials convenient and efficient for use. However, the increasing use of engineered NPs has led to increased exposure potential and concern for human and environmental safety. NPs can enter an organism through various pathways and distribute systemically in the circulatory and lymphatic systems and ultimately into tissues. 1 The biodistribution of NPs might markedly influence their biological effects in vivo, such as in inflammatory and oxidative responses related to cardiopulmonary toxicity. 2, 3 Zinc oxide nanoparticles (ZnO NPs) are commonly used in sunscreens in particle sizes ranging from 70 nm to 100 nm because of strong ultraviolet absorptive properties. ZnO NPs also have potential application in the delivery of therapeutic agents for tumors and autoimmune diseases. [4] [5] [6] In our previous study, we reported the biodistribution of Zn(NO 3 ) 2 in NP PBPK modeling were predictive of 65 ZnO NP biodistribution and accumulative levels in living organisms. Our PBPK model was able to predict the distributions of 
Materials and methods
All animal treatments and experimental protocols for this study were reviewed and approved by the Institutional Animal Care and Use Committee of the National Health Research Institutes (NHRI), Zhunan, Taiwan.
Test NPs
ZnO NPs of 71 nm diameter were purchased from Alfa Aesar (Ward Hill, MA, USA), while ZnO NPs of 10 nm diameter were purchased from NanoScale Corporation (Manhattan, KS, USA). Zn(NO 3 ) 2 was purchased from Showa Corporation (Tokyo, Japan). Radioactive 65 ZnO NPs and 65 Zn(NO 3 ) 2 were generated using the Tsing Hua Open-Pool Reactor (THOR; National Tsing Hua University, HsinChu, Taiwan). Before neutron activation, the surface area, surface charge, shape, and size distribution of cold ZnO NPs were assessed and reported in the previously published paper. 7 For surface chemistry identification, ZnO NPs were subjected to Raman spectroscopic analysis using DXR Raman Microscope (DXR; Thermo Fisher Scientific, Waltham, MA, USA) with DXR 532 nm laser and full-range grating (50-3,500 cm −1 ). For crystalline analysis, each sample (1 g) was filled into a sample holder and subjected to X-ray powder diffraction. The measurements were carried out by powder X-ray diffraction (MiniFlex II, Rigaku Corporation, Tokyo, Japan) with a scan speed of 2° per minute for the scan angle between 10° and 90°. Figure S1A and B are Raman spectra of 10 nm and 71 nm ZnO NPs, respectively, in which the characteristic Zn-O stretching bands are observed at 436 cm −1 and both NPs are not chemically modified on their surface. 10 Figure S2A and B display X-ray diffraction patterns of 10 nm and 71 nm ZnO NPs, respectively, presenting no significant difference between these two NPs. The diffraction peaks for 10 nm ZnO NPs are located at 31 Zn(NO 3 ) 2 were dissolved in 400 μL of distilled water and injected into 6-week-old male ICR mice (0.031-0.032 kg) through a tail vein. 7 The sampling times for accumulation and tissue weight measurements were 1, 2, 4, and 7 hours and 1, 2, 3, 7, and 28 days postinjection. The tissue samples included blood, liver, lung, kidney, spleen, brain, heart, gastrointestinal (GI) tract, and carcass (muscle and bone). Abbreviations: V i , tissue volume; V i,f , percentage tissue volume; BW, body weight; Q Bl , cardiac output rate; Q c , cardiac output constant; Q i , tissue-specific output rate; Q i,f , percentage cardiac output rate; p i (t), partition coefficient at time t; aUc i and aUc Bl , area under the curve of each tissue and blood, respectively; p i,ini , initial value of p i ; p i,max , maximum value of p i ; Tp i,50 , time to reach half maximum p i ; n pi , Hill coefficient of p i ; C i (t), tissue-specific concentration at time t; C i (t=T), tissue-specific concentration estimated by specific time T; k i (t), excretion or elimination rate at time t; k i,min , minimum value of k i ; k i,max , maximum value of k i ; Tk i,50 , time to reach half maximum k i ; n ki , Hill coefficient of k i ; PBPK, physiologically based pharmacokinetics; NP, nanoparticle; Br, brain; ca, carcass; gI, gastrointestinal; lI, liver; KI, kidney.
Model construction
system, 3) excretion and elimination rates are described as first-order processes, and 4) complete equilibrium in a chemical exists between blood and tissue phases. Almost all PBPK models can be described by mass balance equations. (1) where Q C is the cardiac output constant for a 1 kg mice and BW is the body weight (kg). 13 Organ volume constants (V i ) of mice were scaled to body weight based on a previous study.
7 Table 2 lists all physiological parameters used in PBPK modeling. 
Parameterization and validation
Abbreviations: C, concentration; V, tissue volume; Q, Blood flow to organ; p, partition coefficient; k, excretion or elimination rate; Bl, blood; li, liver; Ki, kidney; sp, spleen; lu, lung; Br, brain; he, heart; gI, gastrointestinal; ca, carcass. 
where p i (t) is the time-dependent partition coefficient (−), p i,ini is the initial partition coefficient (−), p i,max is the maximum partition coefficient (−), Tp i,50 is the time constant at 50% maximum partition coefficient (hours), t is the time (hours), and n pi is the Hill coefficient (−). Typically, excretion or elimination rate constant estimates can be determined by a depuration process in a contaminated organism without 65 ZnO NP or 65 Zn(NO 3 ) 2 injection. Therefore, the kinetics of the depuration process,
where 
where k i,min is the minimum excretion or elimination rate constant (h
), k i,max is the maximum excretion or elimination rate constant (h −1 ), Tk i,50 is the time constant at 50% maximum excretion or elimination rate (hours), and n k i is the Hill coefficient (−). TableCurve 2D (Version 5; AISN Software Inc, Mapleton, OR, USA) was used to fit the experimental data to obtain the optimally fitted statistical model. The generated coefficients of determination (r 2 ) can be used to examine the goodness of fit of selected nonlinear statistical models.
To investigate differences in size-and tissue-specific accumulation trends, mean residence times of 65 ZnO NPs and 65 Zn(NO 3 ) 2 in tissues were calculated. Mathematically, mean residence time can be defined as:
where t ī is the mean residence time (hours) and C i (t) is the tissue concentration profile (μg⋅g −1 ). 
where N denotes the number of observations, C o,n is the observed biodistribution data from blood and each tissue of 65 ZnO NPs and 65 Zn(NO 3 ) 2 , and C m,n is the modeled result corresponding to blood-and tissue-specific data point n. Further calibration might be required to obtain the optimal fit of pharmacokinetics to experimental data. To perform further calibration of the experimental data, the estimated tissue-specific excretion or elimination rates and partition coefficients would be adjusted based on our study hypothesis and the characteristics of 
sensitivity analysis
A sensitivity analysis was performed to identify the influence of critical variables in the algorithm on tissue accumulation.
To test sensitivity, the partition coefficients and excretion and elimination rates were increased by 10% to iterate the model simulation and to identify significant changes in the modeled accumulation distribution. The sensitivity ratios were calculated as:
where ∆C is the difference between the resulting and original (Y o ) predicted concentration values, and ∆x is the difference between the resulting and initial (x o ) parameter values.
Results

Particle size-dependent physicochemical parameters
Our results indicated that the calculated tissue partition coefficients of 10 nm .97-0.99), and Hill coefficients were significant (.1) for both. Table 3 shows the estimates of the Hill parameters for brain and carcass partition coefficients. (Figure 3) . Moreover, the concentration of 71 nm 65 ZnO NPs decreased substantially to almost zero from days 3 to 7 in the spleen. Therefore, we used optimized partition coefficients (listed in Table 3 ) to simulate and describe 65 ZnO NPs concentration profiles over time in the lung and spleen ( Figure 3A-F) .
The majority of the experimental concentration profiles of 65 ZnO NPs and 65 Zn(NO 3 ) 2 in the target tissues of mice rapidly increased within a few hours of intravenous injection and decreased thereafter ( Figures 3A-R and 4) , whereas concentrations profiles in the brain and carcass increased and then slightly decreased during the 7-day period ( Figure 3S-X) . The time-dependent increasing functions of the partition coefficients might thus be suitable to describe the biodistributions of 65 ZnO NPs and 65 Zn(NO 3 ) 2 in mice brain and carcass (Table 3) .
During the late phase (days 7-28), we observed that tissue concentration markedly decreased and that our simulation of 65 ZnO NPs barely fit the experimental data. Yet, the simulation of 65 Zn(NO) 3 was well fitted with the experimental data. Therefore, it is likely that 65 ZnO NPs gradually decompose into zinc ion after 7 days. Indeed, similar results were also observed in a previous study. 17 We proposed that the 65 ZnO NPs might decompose after day 7, resulting in a markedly decreasing trend on day 28. For that, we replaced the partition coefficients and excretion or elimination rates of 10 nm and 71 nm 65 ZnO NPs after day 7 with those estimated from 65 Zn(NO 3 ) 2 experimental data. All partition coefficients used for calibration are listed in Table 4 .
Overall, our results indicated that the PBPK simulations with calibration reasonably agreed with the experimentally determined values of the time-dependent 65 ZnO NP and 65 Zn(NO 3 ) 2 concentrations (MAPE ,50%) ( Figure 5 ). Notably, 10 nm 
Mean residence time estimation and sensitivity analysis
We used the experimental accumulation data obtained using Figure 6A , the mean residence times of the majority of tissues ranged from 7 days to 14 days. Generally, the mean residence time of 10 nm ZnO NPs in the spleen had the lowest mean residence time of 4.55 days (95% confidence interval: 1.14-2.07). Figure 7 shows the critical variables in our sensitivity analyses for tissue concentrations during the 7-day period. The sensitivity analyses indicated that 65 Zn(NO 3 ) 2 tissue concentrations were most sensitive to the increased excretion or elimination rate of the liver (k Li , sensitive coefficient: 0.46) and that the partition coefficient of the lung (p Lu ) presented the most sensitive coefficient of 0.54 in 10 nm 65 ZnO NPs. However, parameters that increased in correspondence with a decrease in tissue concentration included the excretion or elimination rates of the GI tract and kidney for all chemicals, the partition coefficients of the GI tract (−0.06) and carcass (−0.32) for 10 nm 65 ZnO NPs, and the partition coefficients of the carcass (−0.14) for 71 nm 65 ZnO NPs.
Discussion
ZnO NP has been proposed to gradually decompose into zinc ion in the biological system. However, our data showed that the tissue kinetics of , we are able to propose that majority of 65 ZnO NP in tissues might decompose after day 7. And incorporating the parameters of zinc ion into 65 ZnO NP model after day 7 would improve the simulation. Our study shows that it is possible to construct a PBPK model for slowly decomposed NPs, by comparing the kinetics of NPs and soluble elements.
critical parameters and associated effects of PBPK model ZnO NPs in mice tissues. In a PBPK model, the partition coefficient is the key parameter affecting accumulation levels in tissues. 18 Although it is often assumed that partitioning between tissues and blood reaches equilibrium after 24 hours, increasing evidence suggests that equilibrium for NPs in specific tissues is reached after several days to several months and that the concentrations in these ZnO NPs failed to accumulate in the lung and its partition coefficients decreased, suggesting that this mechanism in the lung might not be crucial in long-term biodistribution.
Potential mechanisms for the biodistribution of NPs
The potential mechanisms for the biodistribution of NPs are complicated. Several factors such as interactions with biological barriers and NP properties (composition, size, core properties, and surface modifications) have been shown to significantly influence the biodistribution and blood circulation half-life of circulating NPs. A study indicated that partition coefficients of tissues or blood might be influenced by factors including blood flow and the turnover rate of each tissue, tissue affinity, and lipid composition. 26 An increased timedependent partition coefficient in the liver in mice exposed to polychlorinated biphenyls was identified. 27 ZnO NPs might be persistent in the approximately neutral surfactant fluid or cytosol, yet it is rapidly converted to Zn 2+ when ZnO NPs internalized into the acid environment of the lysosome. 17 From our previous studies and in vitro experiments, we proposed that ZnO NPs would decompose, release Zn
2+
, and upregulate MT protein after endocytosis (Figure 8 ). Sadhu and Gedamu reported that the upregulation of MT decreased dynamically with time after exposure to Zn. 28 MT binds to intracellular Zn
and increases their accumulation in cells (Figure 8 ). When MT protein decreases at later time points, Zn 2+ ions are pumped out of the cells by the Zn transporter, reenter the circulation, and are subsequently stored in muscle and bone (referred to as carcass in this study). 29, 30 Therefore, the tissue partition coefficients of ZnO NPs might change time-dependently. Indeed, our results showed that the partition coefficients of ZnO NPs are dependent on time after exposure and might be affected by the decomposition of ZnO NPs (Figure 8) . Also, the results have a good prediction when we replaced the partition coefficients and excretion or elimination rates of 10 nm and 71 nm ZnO NPs with that of Zn 2+ after day 7 exposure. Furthermore, NPs are reportedly readily uptaken by phagocytic cells in the liver, spleen, lung, and kidneys. 31 Therefore, ZnO NPs quickly distribute to these organs within 24 hours of exposure. Proteins associated with the surfaces of NPs are recognized by macrophages and might modulate the translocation and redistribution of NPs from blood by organs with an reticuloendothelial system. 32 In addition, the uptake and internalization of NPs in the brain might be facilitated by the formation of a biocorona, with plasma proteins on the surface of NPs, which allows for the crossing of the brain-blood barrier. [33] [34] [35] Our data indicated that the relationship between time and partition coefficients in the brain and carcass differed from those in other tissues. Considering the unique biodistribution characteristics of ZnO NPs and Zn
, we used the Hill equation to describe partitioning between blood and tissues in a time-dependent manner. The time-dependent partition coefficients fitted well with the measurement data and enabled the construction of our PBPK model for ZnO NPs.
Implications
We observed that the partition coefficients of the brain (p Br ) and carcass (p Ca ) increased time-dependently. This indicates that irrespective of phase and size, ZnO NPs and Zn(NO 3 ) 2 preferentially redistribute to the brain and carcass at later time points after exposure. With high partition coefficient, the 10 nm ZnO NPs tend to redistribute and accumulate in the brain tissue. Although p Br and p Ca were relatively low following a single dose of the Zn compounds, multiple dosing for a long duration could potentially increase the accumulation of chemicals in the brain and carcass. Zn 2+ ions are abundant in the brain and play crucial roles in learning and memory. 36 However, Zn overdose can cause spatial reference memory deficit in animals. It has been identified that ZnO NPs have the potential ability to damage and kill neural stem cells in mice. 38 Therefore, in future research, the cumulative and hazardous properties of ZnO NPs in the brain should be considered in long-term health assessments of brain damage and memory deficit.
The biodistribution of NPs is highly influenced by the cellular uptake of NPs through phagocytosis by the mononuclear phagocytic system. NPs can accumulate in phagocytic cells of specific organs including the liver, spleen, lung, kidney, and brain or redistribute to the lymphatic fluid. According to previous study, phagocytizing cells rapidly capture NPs until their saturation, constitute a major reservoir in richly perfused organs, including the spleen, liver, bone marrow, lungs, heart, and kidneys, and store 83% NPs in these organs 120 hours after injection. 39 To more comprehensively understand the role of the mononuclear phagocytic system in the biodistribution of NPs, we will include mononuclear phagocytic system subcompartments in these organs when we construct PBPK models for NPs in future studies.
A report investigated and compared ZnO NP and zinc chloride contents in the blood and observed that although ZnO NPs partly dissolve in gastric conditions (13%-14%), particles administered in various states produce different biodistribution profiles. 40 Although studies have demonstrated that ZnO NPs can dissolve in tissues and release Zn 2+ within hours, the metabolic mechanisms leading to the various biodistribution profiles of NPs and ions remain unclear and warrant further investigation. 1, 40 Given that the exposure doses and excretion or elimination rates of each tissue are known, a PBPK model suitable for transfer within various exposure routes (intravenous, inhalation, and oral) could be constructed. 41, 42 International 
